Artios Pharma, a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, has appointed Dr Graeme Smith as its Chief Scientific Officer (CSO). Graeme has more than 25 years’ experience in oncology research, with significant expertise and in-depth knowledge in the field of DDR. He was co-inventor of Lynparza™ (olaparib), an approved treatment for advanced ovarian cancer and the first DDR targeted product to reach the market.
As CSO at Artios, Graeme will play an important role in driving the Company’s pipeline of first-in-class DDR targeted programmes to the clinic, including its lead programme against the DNA polymerase Pol Theta (PolƟ). Furthermore, his extensive academic and industrial DDR network will support Artios in identifying new pipeline opportunities to further establish the Company as a leader in the field of DDR.
Graeme joins Artios from AstraZeneca, where he held the position of Senior Director of Bioscience within the Oncology Innovative Medicines and Early Development (IMED) division.
Dr Niall Martin, Chief Executive Officer of Artios Pharma, said:
“We are delighted to welcome Graeme to our management team as Chief Scientific Officer. His in-depth experience of DDR drug discovery in both large pharma and biotech will significantly help Artios as we continue to build a pipeline of highly innovative DDR programmes. With a proven team now strengthened even further, an exciting product pipeline in development, key collaborations in the field of DNA repair, and a strong investor base, Artios is leading the development of next generation DDR targeted cancer therapies.”